| William P Johnson Jr, MD | |
|
108 Island Professional Park, St Simons Island, GA 31522-2880 | |
| (912) 268-4372 | |
| Not Available |
| Full Name | William P Johnson Jr |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine - Emergency Medical Services |
| Location | 108 Island Professional Park, St Simons Island, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295756757 | NPI | - | NPPES |
| R0961 | Other | KY | LICENSE |
| 01063853A | Other | IN | INDIANA STATE LICENSE |
| Entity Name | Georgia Emergency Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528098290 PECOS PAC ID: 1052216389 Enrollment ID: O20031201000427 |
News Archive
EntreMed, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer, today reported that three months following administration with ENMD 0996, preclinical animal models showed inhibition of metastases. Data presented demonstrated that ENMD 0996 specifically blocks the activity of basic fibroblast growth factor (FGF-2), a naturally-occurring protein that stimulates angiogenesis, but had no effect on other angiogenesis stimulators.
In attempt to identify biological markers, or biomarkers, that can signal the presence of cancer and help oncologists determine the best course of therapy when cancer is present, teams of investigators are scouring stored tissue samples obtained from thousands of cancer patients.
Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference.
Many medical tests that once required sending samples to a laboratory and waiting for results can now be rapidly performed at the patient's bedside. As these point-of-care testing (POCT) technologies are increasingly integrated into patient care, careful attention is needed to protect patient safety and avoid medical errors, according to this month's special issue of Point of Care: The Journal of Near-Patient Testing & Technology.
› Verified 2 days ago
| Entity Name | Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477001972 PECOS PAC ID: 7911811435 Enrollment ID: O20161012000482 |
News Archive
EntreMed, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer, today reported that three months following administration with ENMD 0996, preclinical animal models showed inhibition of metastases. Data presented demonstrated that ENMD 0996 specifically blocks the activity of basic fibroblast growth factor (FGF-2), a naturally-occurring protein that stimulates angiogenesis, but had no effect on other angiogenesis stimulators.
In attempt to identify biological markers, or biomarkers, that can signal the presence of cancer and help oncologists determine the best course of therapy when cancer is present, teams of investigators are scouring stored tissue samples obtained from thousands of cancer patients.
Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference.
Many medical tests that once required sending samples to a laboratory and waiting for results can now be rapidly performed at the patient's bedside. As these point-of-care testing (POCT) technologies are increasingly integrated into patient care, careful attention is needed to protect patient safety and avoid medical errors, according to this month's special issue of Point of Care: The Journal of Near-Patient Testing & Technology.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William P Johnson Jr, MD 108 Island Professional Park, St Simons Island, GA 31522-2880 Ph: (912) 268-4372 | William P Johnson Jr, MD 108 Island Professional Park, St Simons Island, GA 31522-2880 Ph: (912) 268-4372 |
News Archive
EntreMed, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer, today reported that three months following administration with ENMD 0996, preclinical animal models showed inhibition of metastases. Data presented demonstrated that ENMD 0996 specifically blocks the activity of basic fibroblast growth factor (FGF-2), a naturally-occurring protein that stimulates angiogenesis, but had no effect on other angiogenesis stimulators.
In attempt to identify biological markers, or biomarkers, that can signal the presence of cancer and help oncologists determine the best course of therapy when cancer is present, teams of investigators are scouring stored tissue samples obtained from thousands of cancer patients.
Molecular Partners AG, a pioneer in the development of DARPins as next generation protein therapeutics, has announced the closing of its Series B equity investment round securing CHF 46 million (€ 30 million, $ 45 million).
Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and adolescents with severe, uncontrolled asthma, according to research presented at the ATS 2021 International Conference.
Many medical tests that once required sending samples to a laboratory and waiting for results can now be rapidly performed at the patient's bedside. As these point-of-care testing (POCT) technologies are increasingly integrated into patient care, careful attention is needed to protect patient safety and avoid medical errors, according to this month's special issue of Point of Care: The Journal of Near-Patient Testing & Technology.
› Verified 2 days ago